Hana Sees Good Progression With Alocrest

A Phase I trial evaluating Hana Biosciences’ Alocrest, a cancer treatment, demonstrated promising results.

The drug is an encapsulated formulation of vinorelbine tartrate and is intended to treat certain solid tumor cancers and lymphomas.

The trial enrolled 30 subjects with advanced solid tumors, most of whom were classified as heavily pre-treated. The study produced a disease control rate of 47 percent, including three out of four elderly nonsmall cell lung cancer subjects who achieved stable disease, the company said.